The Lancet medical journal said on Tuesday “serious scientific questions” had been brought to its attention about the validity of the data behind a widely cited and already corrected study on the dangers of the use ofthe anti-malarial drug hydroxychloroquine in hospitalizedpatients with COVID-19.
The Lancet study published on May 22 found that the anti-malarial drug hydroxychloroquine, which US President Donald Trump took and has urged others to use, was tied to an increased risk of death in hospitalized COVID-19 patients.
Several clinical trials were put on hold after the study was published.
For more coronavirus news, visit our dedicated page.
The article, called “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,” was an observational study - meaning it compiled real world data, rather than conducting a traditional clinical trial - and used data provided byhealthcare data analytics firm Surgisphere.
The Lancet last week issued a correction to the study regarding the location of some patients following criticism of its methodology, but said the conclusions were not changed.
For all the latest headlines follow our Google News channel online or via the app
Also last week, nearly 150 doctors signed an open letter to the journal calling the article’s conclusions into question and asking to make public the peer review comments that led to it being published.
- Coronavirus: US hospitals cut back use of hydroxychloroquine touted by Trump
- Hydroxychloroquine combination risky for cancer patients with coronavirus: Study
- Clinical trial with hydroxychloroquine on coronavirus patients suspended: WHO
- Coronavirus: France stops using hydroxychloroquine for COVID-19 patients